logotype
Baillargeon JP 2012

Jean-Patrice Baillargeon, PhD

Associate Professor

Université de Sherbrooke

Department : Médecine et Physiologie/Biophysique

3001, 12e Avenue Nord, Sherbrooke, J1H 5N4

E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Tel : 819 346-1110 ext : 15241

Fax: 819-564-5292

 

Fields of research:

Polycystic ovary syndrome (PCOS) is a common condition affecting 6-10% of women of childbearing age. It is the most frequent endocrine disorder among young women in Canada. PCOS is defined by hyperandrogenism, chronic anovulation and/or polycystic ovaries. Accordingly, affected women usually seek medical attention for esthetical complains (hair growth, acnea) or infertility. Despite all the effort made in finding the causal factor of this disorder, many questions remain unanswered regarding the mechanisms by which insulin resistance or insulin produces hyperandrogenemia. Dr. Jean-Patrice Baillargeon’s research program aims to elucidate the role of non-esterified fatty acid (NEFA) into the pathogenesis of PCOS. Furthermore, lifestyle modification is essential to reduce PCOS lipotoxicity and the burden of obesity in Canada. Dr. Baillargeon also seeks to assess the best approaches to support primary care for obesity management. The ultimate goal of his research is thus to reduce the impact of obesity, mainly on women’s health, and facilitate rapid knowledge transfer to clinical application through a translational approach. Briefly, his research program is composed of 2 principal aims; 1) Determin the impacts of NEFAs on the induction of androgenic hypersecretion and associated mechanisms. This aim is tested in vivo in women with or at risk for PCOS, and in vitro in bovine, canine or human ovarian and/or adrenal gland cell cultures. This part of the project is innovative as clinical aspects are in continuity with fundamental works in order to maintain a bench-to-beside relationship. 2) Evaluate the impacts of management of obesity, using lifestyle strategies, integrated to primary care practices and the fertility clinic.

Resume of recent results:

In the past years, we have shown a role for fatty acids in the development of hyperandrogenemia, the main characteristic of polycystic ovary syndrome, in adrenal gland and more recently, in theca ovarian primary cell culture. These data are supported by studies conducted in an animal model and human participants. In the JCR:LA cp/cp rat PCOS model, we showed increased ovarian fatty acid uptake in comparison to control rats. Moreover, these PCOS rats were characterised by a positive association between testosterone levels and fatty acid uptake. Moreover, we demonstrated in women undergoing in vitro fertilisation treatment a positive correlation between fatty acid and testosterone levels present in the follicular fluid. This relation may be dependent upon increased inflammation and altered fatty acid β-oxidation. In these women, we also evidenced a negative association between follicular testosterone levels and percentage of fertilized oocytes.

Laboratory members:

 

Name

Position

Email address

Matéa Belan

PhD Student

This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

Karine Duval

Research assistant

This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

Samuel Leblanc

PhD Student

This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

Farrah Jean-Denis

Research Coordinator

This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

Christian-Alexandre Castellano

Postdoctoral Fellow

This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

Soren Harnois-Leblanc

MSc Student

This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

Joanie Faubert MSc Student  This email address is being protected from spambots. You need JavaScript enabled to view it.
Allexandre Connolly MSc Student  This email address is being protected from spambots. You need JavaScript enabled to view it.

 

 Labo Baillargeon 2013-06-12rd

List of publications:

Articles of original research - Published (excluding review articles)

  1. Côté S, Guay SP, Allard C, Brisson D, Perron P, St-Pierre J, Gaudet D, Baillargeon JP, Guérin R, Hivert MF, Bouchard L. PPARGC1α gene DNA methylation variations in human placenta mediate the link between maternal hyperglycemia and leptin levels in newborns. Clin Epigenetics. 2016; Jun 22; 8:72.
  2. Ardilouze JL, Ménard J, Gobeil FJ, Gagnon-Auger M, Houde G, Pesant MH, Rabasa-Lhoret R, Baillargeon JP. CSII: Longer Catheter Usage Time, a Reasonable Goal. J Diabetes Sci Technol. 2016; 10(4):989-90.
  3. Castellano CA, Baillargeon JP, Nugent S, Tremblay S, Fortier M, Imbeault H, Duval J, Cunnane SC. Regional brain glucose hypometabolism in young women with polycystic ovary syndrome: possible link to insulin resistance. PLoS One. 2015; 10(12):e0144116.
  4. Houde AA, Ruchat SM, Allard C Baillargeon JP, St-Pierre J, Perron P, Gaudet D, Brisson D, Hivert MF and Bouchard L. LRP1, BRD2 and CACNA1D: new candidate genes in fetal metabolic programming of newborns exposed to maternal hyperglycemia. Epigenomics. 2015; 7(7):1111-22.
  5. Duval K, Langlois MF, Carranza-Mamane B, Pesant MH, Hivert MF, G. Poder T, B. Lavoie HB, Ainmelk Y, St-Cyr Tribble D, Laredo S, Greenblatt E, Sagle M, Waddell G, Belisle S, Riverin D; Jean-Denis F, Belan M, Baillargeon JP. The Obesity-Fertility Protocol: a randomized controlled trial assessing clinical outcomes and costs of a transferable interdisciplinary lifestyle intervention, before and during pregnancy, in obese infertile women. BMC Obesity. 2015; Dec 1; 2:47.
  6. Thibault V, Morrisset AS, Brown C, Carpentier AC, Baillargeon JP, Langlois MF, Gagnon C. The increase in serum 25-hydroxyvitamin D following weight loss and does not contribute to the improvement in insulin sensitivity, insulin secretion and ß-cell function. Br J Nutrition. 2015; 114(2):161-8.
  7. Sotornik R, Baillargeon JP*, Ménard J, Gagnon-Auger M, Brassard P, Ardilouze JL. Regulation of blood flow in adipose tissue: involvement of the cholinergic system. Am J Physiol Endocrinol Metab. 2015; 309(1):E55-62.
  8. Baillot A, Baillargeon JP, Brown C, Langlois MF. The 6-minute walk test reflects functional capacity in primary care and obese patients. International Journal of Sports Medecine 2015 Mar 3. [Epub ahead of print]. PMID: 25734909.
  9. Gervais A. Battista MC, Carranza-Mamane B, Lavoie HB, Baillargeon JP. Follicular fluid concentrations of lipids and their metabolites are associated with intra-ovarian gonadotropin-stimulated androgen production in women undergoing in vitro fertilization. Journal of Clinical Endocrinology and Metabolism. Feb 2015 19:jc20143649. [Epub ahead of print].
  10. Bellanger S, Benrezzak O, Battista MC, Naimi F, Labbé S, Frisch F, Normand-Lauzière F, Gallo-Payet N, Carpentier AC, Baillargeon JP. Experimental dog model for assessment of fasting and postprandial fatty acid metabolism: Pitfalls and Feasibility. Lab Anim. 2015. pii: 0023677214566021. PMID: 25563731.
  11. Kunach M; Noll C, Phoenix S, Guérin B, Baillargeon JP, Turcotte A, Carpentier AC. Effect of Gender and Impaired Glucose Tolerance on Organ-Specific Dietary Fatty Acid Metabolism in Humans. Diabetes Journal 2014 pii: DC_141166. [Epub ahead of print]. PMID: 2550374
  12. Baillargeon JP, St-Cyr-Tribble D, Xhignesse M, Grant A, Brown C, Langlois MF. Impact of an integrated obesity management system on patient’s care – Research protocol, BMC Obesity, Sep. 2014, 1:19 doi: 10.1186/s40608-014-0019-z.
  13. Leblanc S, Battista MC, Noll C, Hallberg A, Gallo-Payet N, Carpentier AC, Vine DF, Baillargeon JP. Angiotensin II type 2 receptor stimulation improves fatty acid ovarian uptake andhyperandrogenemia in an obese rat model of polycystic ovary syndrome. Endocrinology 2014:en20141185. [Epub ahead of print] PMID: 24971613.
  14. Desgagnés V, Hivert MF, St-Pierre J, Guay SP , Baillargeon JP, Perron P, Gaudet D, Brisson D, Bouchard L. Epigenetic dysregulation of the igf system in placenta of newborns exposed to maternal impaired glucose tolerance. Epigenomics. 2014;6(2):193-207. PMID: 24811788.
  15. Labbé SM,Noll C, Grenier-Larouche T, Kunach M, Bouffard, L, Phoenix S, Guerin B, Baillargeon JP, Langlois MF, Turcotte É, Carpentier AC. Improved cardiac function and dietary fatty acid metabolism after modest weight loss in subjects with impaired glucose tolerance. Am J Physiol Endocrinol Metab 2014 ;306(12):E1388-96.
  16. Baillot A, Audet M, Baillargeon JP, Dionne I, Valiquette L, Rosa-Fortin MM, Abou Chakra CN, Comeau E, Langlois MF. Impact of physical activity and fitness in class II and III obese individuals: a systematic review. Obes Rev. 2014: 721-39.
  17. Houde AA, St-Pierre J, Hivert MF, Baillargeon JP, Perron P, Gaudet D, Brisson D, Bouchard L. Placental Lipoprotein Lipase DNA Methylation Levels Are Associated with gestational diabetes mellitus and maternal and cord blood lipid profiles . Journal of Developmental Origins of Health and Disease, 2014; 5(2):132-141.
  18. Biet M, Morin N, Benrezzak O, Naimi F, Bellanger S, Bailllargeon JP, Chouinard L, Gallo-Payet N, Carpentier AC, Dumaine R. Lasting alterations of the cardiac sodium current by short term hyperlipidemia as a mechanism for initiation of cardiac remodeling. Am J Physiol Heart Circ Physiol. 2014; 306(2):H291-7.
  19. Unfer V, Carlomagno G, Papaleo E, Vailati S, Candiani M, Baillargeon JP. Hyperinsulinemia Alters Myoinositol to D-chiroinositol Ratio in the Follicular Fluid of Patients With PCOS. Reprod Sci. 2014 4;21(7):854-858
  20. Houde AA, Guay SP, Desgagné V, Hivert MF, Baillargeon JP, St-Pierre J, Perron P, Gaudet D, Brisson D, Bouchard L. Adaptations of placental and cord blood ABCA1 DNA methylation profile to maternal metabolic status.Epigenetics 10; 8(12) :1289-302.
  21. Castellano CA , Baillargeon JP , Plourde M, Briand SI, Angers P, Giguère A, Matte JJ. Dietary conjugated αalpha-linolenic acid did not improve glucose tolerancein a neonatal pig model. Eur J Nutr. 2014 ; 53(3):761-8
  22. Ruchat SM, Houde AA, Voisin G, St-Pierre J, Perron P, Baillargeon JP, Gaudet D, Hivert MF, Brisson D, Bouchard L. Gestational Diabetes Mellitus Epigenetically Affects Genes Predominantly Involved in Metabolic Diseases. Epigenetics, 2013: 8(9): 935-943.
  23. Bouchard DR, Langlois MF, Boisvert-Vigneault K, Farand P, Paulin M, Baillargeon JP*. Pilot study : Can Older Inactive Adults Learn how to Reach the Required Intensity of Physical Activity Guidelines? Clinical Interventions in Aging2013; 8:1-8.
  24. Bouchard DR, Porneala B, Janssen I, Langlois, MF, Baillargeon JP, Pencina M, D’Agostino Sr RB, Fox CS, Meigs JB, Hivert MF. Risk of Type 2 Diabetes and Cumulative Excess Weight Exposure in the Framingham Offspring Study. J Diabetes Complications2013; 27(3):214-8
  25. Shum M, Pinard S, Guimond MO, Labbé SM, Roberge C, Baillargeon JP, Langlois MF, Alterman M, Wallinder C, Hallberg A, Carpentier AC, Gallo-Payet N. Angiotensin II type 2 receptor promotes adipocyte differentiation and restores adipocyte size in high fat/high fructose diet-induced insulin resistance in rats. Am J Physiol Endocrinol Metab. 2013; 304(2):E197-210. Grant : CDA OG-3-10-3021-NG.
  26. Trottier A, Battista MC, Geller DH, Moreau B, Carpentier AC, Simoneau-Roy J, Baillargeon JP*. Adipose Tissue Insulin Resistance in Peripubertal Girls with First-Degree Family History of Polycystic Ovary Syndrome. Fertil Steril.2012; 98(6):1627-34.
  27. ORIGIN Trial Investigators (including Baillargeon J), Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. New Engl J Med 2012; 367(4):319-28. PubMed ID: 2686416.
  28. Raissouni N, Kolesnikov A, Purushothaman R, Sinha S, Bhandari S, Bhangoo A, Malik S, Mathew R, Baillargeon JP, Hernandez MI, Rosenbaum M, Ten S, Geller D. Altered glucose disposition and insulin sensitivity in peri-pubertal first-degree relatives of women with polycystic ovary syndrome.Int J Pediatr Endocrinol. 2012; 2012(1):14.
  29. Bouchard DR, Baillargeon JP, Domingue ME, Langlois MF. Age Differences in Expectations and Readiness Regarding Lifestyle Modifications in Individuals at High Risk of Diabetes. Arch Phys Med Rehabil. 2012; 93(6):1059-64. Lawson Fondation GRT 2008-009.
  30. Henderson M, Baillargeon JP, Rabasa-Lhoret R, Chiasson JL, Hanley J, Lambert M. Estimating insulin secretion in youth using simple indices derived from the oral glucose tolerance test. Diabetes Metab. 2012; 38(4):309-1
  31. Bouchard D, Baillargeon JP, Gagnon C, Brown C, Langlois, MF. Impact of Contact Frequency with the Exercise Specialist within a Multidisciplinary Team on Response of Prediabetics to Lifestyle Intervention. Diabetes Res Clin Pract 2012; 96(2):129-134. Lawson Fondation GRT 2008-009.
  32. Bellanger S,Battista MC, Fink GD, Baillargeon JP*. Saturated fatty acid exposure induces androgen overproduction in bovine adrenal cells, Steroids 2012; 77 (4): 347-353. CIHR MOP 97965.
  33. Pesant MH, Desmarais G, Fink G, Baillargeon JP*. Reference ranges for total and calculated free and bioavailable testosterone in a young healthy women population with normal menstrual cycles. Clinical Biochemistry 2012; 45(1-2): 148-150.
  34. Gagnon C, BrA cost-effective moderate-intensity interdisciplinary weight management programme for individuals with pre-diabetes. Diabetes Metab. 2011; 37(5): 410-418.
  35. Bouchard D, Langlois MF, Brochu M, Dionne I, Baillargeon JP*. Metabolically Healthy Obese Women and Functional Capacity. Metab Syndr Relat Disord 2011; 9(3):225-9.
  36. Henderson M, Rabasa-Lhoret R, Bastard JP, Chiasson JL, Baillargeon JP, Hanley JA, Lambert M. Measuring insulin sensitivity in youth: how do the different indices compare to the gold standard method? Diabetes & Metabolism 2011;37(1):72-8.
  37. Pesant MH, Baillargeon JP*. Clinically useful predictors of conversion to abnormal glucose tolerance in wen with polycystic ovary syndrome. Fertil Steril 2011; 95(1):210-215.
  38. Wickham EP 3rd, Cheang KI, Clore JN, Baillargeon JP, Nestler JE. Total and high-molecular weight adiponectin in women with the polycystic ovary syndrome. Metabolism2011; 60(3):366-72.
  39. Zhao L, Li W, Han F, Hou L, Baillargeon JP, Kuang H, Wang Y, Wu X. Berberine reduces insulin resistance induced by dexamethasne in theca cells in vitro. Fertil Steril 2011; 95(1):461-3.
  40. Maymone AC, Baillargeon JP, Ménard J, Ardilouze JL. Oral hypoglycemic agents for gestational diabetes mellitus? Expert Opin Drug Saf. 2011; 10(2):227-38.
  41. Gagnon-Auger M, Du Souich P, Baillargeon JP, Martin E, Brassard P, Ménard J, Ardilouze JL. Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogues in obese subjects with type 2 diabetes mellitus: a pharmacokinetic and pharmacodynamic study. Diabetes Care 2010; 33(12): 2502-2507.
  42. Gagnon C, Baillargeon JP*, Desmarais G, Fink G. Prevalence and Predictors of Vitamin D Insufficiency in Women of Reproductive Age Living in Northern Latitude. Eur J Endocrinol 2010; 163(5): 819-
  43. Gagnon C, Ménard J, Bourbonnais A, Ardilouze JL, Baillargeon JP, Carpentier A, Langlois MF. Comparison of Foot-to-Foot and Hand-to-Foot Bioelectrical Impedance Methods in a population with a Wide Range of Body Mass Indices. Metab Syndr Relat Disord.2010; 8(5):437-441.
  44. Kong W, Langlois MF, Kamga-Ngandé C, Gagnon C, Brown C, Baillargeon JP*. Predictors of success to weight-loss intervention program in individuals at high risk for type 2 diabetes. Diabetes Res Clin Pract. 2010; 90(2):147-53. Grant: Lawson Fondation.
  45. Pelletier L, Baillargeon JP*. Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice. Fertil Steril 2010; 94(7):2665-9.
  46. Baillargeon JP*, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling Between Insulin and Release of a D-Chiro-Inositol-Containing Inositolphosphoglycan Mediator of Insulin action in Obese women with Polycystic Ovary Syndrome. Metab Syndr Relat Disord 2010; 8(2):127-36.
  47. Walter M, Philotheou A, Bonnici F, Ziegler AG, Jimenez R, NBI-6024 Study Group (including Baillargeon JP). No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diabetes Care 2009; 32(11):2036-40.
  48. Beriault K, Carpentier AC, Gagnon C, Ménard J, Baillargeon JP, Ardilouze JL, Langlois MF. Reproducibility of the 6-minute walk test in overweight and obese adults. Int J Sports Med 2009; 30:725-727.
  49. Kamga-Ngandé CN, Carpentier AC, Nadeau-Marcotte F, Ardilouze JL, Baillargeon JP, Bellabarba D, Houde G, Langlois MF. Effectiveness of a multidisciplinary program for management of obesity: the Unité d’Enseignement, de Traitement et de Recherche sur l’Obésité (UETRO) Database study. Metab Syndr Relat Disord 2009; 7(4):297-304.
  50. Lavoie F, Frisch F, Brassard P, Normand-Lauzière F, Cyr D, Gagnon R, Drouin R, Baillargeon JP, Carpentier AC. Relationship between total and high molecular weight adiponectin levels and plasma non-esterified fatty acid NEFA tolerance during enhanced intravascular triacylglycerol lipolysis in men. J Clin Endocrinol Metab 2009; 94(3):998-1004.
  51. Villeneuve MC, Ostlund Jr RE, Baillargeon JP*. Hyperinsulinemia is Closely Related to Low Urinary Clearance of D-Chiro-Inositol in Brothers of Women with Polycystic Ovary Syndrome and Control Men. Metabolism 2009; 58(1):62-8. Grant: FRSQ #2834.
  52. Papaleo E, Unfer V, Baillargeon JP, Fusi FM, Occhi F, De SantisL. Myo-inositol may improve in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009; 91(5):1750‑4.
  53. Cheang KI, Baillargeon JP, Essah PA, Ostlund Jr RE, Apridonize T, Islam L, Nestler JE. Insulin-Stimulated Release of D-Chiro-Inositol-Containing Inositolphosphoglycan Mediator Correlates with Insulin Sensitivity in Women with Polycystic Ovary Syndrome. Metabolism 2008; 57(10):1390-7.
  54. Baillargeon JP, Nestler JE, Ostlund Jr RE, Apridonidze T, Diamanti-Kandarakis E. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. Hum Reprod 2008; 23(6):1439-46.
  55. Brassard P, Frisch F, Lavoie F, Cyr D, Bourbonnais A, Cunnane SC, Patterson BW, Drouin R, Baillargeon JP, Carpentier AC. Impaired plasma non-esterified fatty acid tolerance is an early defect in the natural history of type 2 diabetes. J Clin Endocrinol Metab 2008; 93(3): 837-844.
  56. Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi FM, Brigante C, Guido M, Ilaria C, Ferrari A. Myo-Inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction. Gynecol Endocrinol 2007; 23(12): 700-703.
  57. Baillargeon JP*, Carpentier AC, Donovan D, Fortin M, Grant A, Simoneau-Roy J, St-Cyr-Tribble D, Xhignesse M, Langlois MF. Integrated obesity care management system – Implementation and Research Protocol. BMC Health Services Research 2007;7Grants: CIHR PHE78707, FRSQ #5635.
  58. Baillargeon JP*, Carpentier AC. Brothers of women with polycystic ovary syndrome are characterized by insulin resistance, decreased glucose tolerance and other metabolic anomalies. Diabetologia 2007; 50(12): 2424-2432. Grants: CIHR MOP62946, FRSQ #2834
  59. Baillargeon JP*, Carpentier AC. Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. Fertil Steril 2007; 88(4): 886-893. Grants: CIHR MOP62946, FRSQ #2834
  60. Gagnon C, Baillargeon JP*. Suitability of recommended limits for fasting glucose tests in women with polycystic ovary syndrome. CMAJ 2007; 176(7): 933-938.Grant: FRSQ #2834
  61. Carpentier AC, Brassard P, Lavoie F, Frisch F, Bourbonnais A, Cyr D, Giguère R, Baillargeon JP. Mechanism of insulin-stimulated clearance of plasma non-esterified fatty acids in humans. Am J Physiol Endocrinol Metab 2007; 292(3): 693-701.
  62. Ménard J, Payette H, Dubuc N, Baillargeon JP, Maheux P, Ardilouze JL. Quality of life improvement in type 2 diabetes patients under intensive multitherapy. Diabetes & Metabolism 2007; 33(1): 54-60.
  63. Baillargeon JP*, Diamanti-Kandarakis E, Ostlund Jr RE, Apridonidze T, Iuorno M J, Nestler JE. Altered D-Chiro-Inositol Metabolism in Women With Polycystic Ovary Syndrome. Diabetes Care 2006; 29(2): 300-305.
  64. Ménard J, Payette H, Baillargeon JP, Maheux P, Lepage S, Tessier D, Ardilouze JL. Efficacy of intensive multitherapy for patients with type 2 diabetes mellitus: a randomized controlled trial. CMAJ 2005; 173(12): 1457‑66.
  65. Carpentier AC, Frisch F, Cyr D, Généreux P, Patterson BW, Giguère R, Baillargeon JP. On the suppression of plasma non-esterified fatty acids by insulin during enhanced intravascular lipolysis in humans. Am J Physiol Endocrinol Metab 2005; 289(5): E849-856.
  66. Baillargeon JP*, McClish DK, Essah PA, Nestler JE. Association Between the Use of Low-Dose Oral Contraceptives and Cardiovascular Disease: A Meta-Analysis. J Clin Endocrinol Metab 2005; 90(7): 3863–3870.
  67. Baillargeon JP*, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in lean women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004; 82(4): 893-902.
  68. Jakubowicz DJ, Essah PA, Seppälä M, Jakubowicz S, Baillargeon JP, Koistinen R, Nestler JE. Reduced Serum Glycodelin and Insulin-Like Growth Factor-Binding Protein-1 in Women with Polycystic Ovary Syndrome during First Trimester of Pregnancy. J Clin Endocrinol Metab 2004; 89(2): 833-839.
  69. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Apridonidze T, He N, Nestler JE. Metformin Therapy Increases Insulin-Stimulated Release of D-Chiro-Inositol-Containing Inositolphosphoglycan Mediator in Women with Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2004; 89(1): 242-249.
  70. Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, Nestler JE. Effects of D-Chiro-Inositol in Lean Women with the Polycystic Ovary Syndrome. Endocrine Practice 2002; 8(6): 417-423.
  71. Baillargeon JP, Lepage S, Larrivée L, Roy MA, Maheux P. Intensive surveillance and treatment of dyslipidemia in the postinfarct patient: evaluation of a nurse-oriented management approach. Can J Cardiology 2001; 17(2): 169-175.
  72. Baillargeon JP, Pek B, vanRossum N, Teijeira J, Poisson J, Langlois MF. Combined surgery for coronary artery disease and pheochromocytoma. Can J Anesth 2000; 47(7): 647-652.

Articles of original research - Accepted (excludind review articles)

  1. Belan M, Pelletier C, Baillargeon JPAlanine aminotransferase is a marker of lipotoxicity consequences and hyperandrogenemia in women with polycystic ovary syndrome.Metabolic Syndrome & Related Disorders. 2016 (accepté).
  2. Thibault V, Morrisset AN, Brown C, Carpentier AC, Baillargeon JP, Langlois MF, Gagnon C. The increase in serum 25-hydroxyvitamin D following weight loss and does not contribute to the improvement in insulin sensitivity, insulin secretion and ß-cell function, Bristish Journal of Nutrition. 2015 Feb. (accepted with minor revision)

Review articles published in peer reviewed journals

  1. Faubert J, Battista MC, Baillargeon JP. Physiology and endocrinology symposium: Insulinaction and lipotoxicity in the development of polycystic ovary syndrome: A review. J Anim Sci. 2016; 94(5):11803-11.
  2. Carreau, AM, Baillargeon JP*. PCOS in adolescence and type 2 diabetes. Curr Diab Report 2015 Jan; 15(1):564. doi: 10.1007/s11892-014-0564-3. PMID: 25398203.
  3. Bouchard DR, Baillargeon JP, Langlois MF. REVIEW: The Independent Effect of Age groups on the Effectiveness of Lifestyle Intervention. Current Obesity Reports 2013; 2:107-119.
  4. Gallo-Payet N, Shum M, Baillargeon JP, Langlois MF, Wallinder C, Alterman M, Hallberg A, Carpentier AC. AT2 receptor agonists: Exploiting the beneficial arm of Ang II signaling. Curr Hypert Rev.2012; 8(1): 47-59
  5. Ardilouze JA, Mahdavian M, Baillargeon JP, Hivert MF. Correspondence on Glucose challenge test for detecting gestational diabetes mellitus: a systematic review.Br J Obstet Gynecol 2012; 119(10): 1283.
  6. Battista MC, Hivert MF, Duval K, Baillargeon JP*. Intergenerational cycle of obesity and diabetes. How can we reduce the burdens of these conditions on the health of future generations? Experimental Diabetes Research 2011 2011(596060): 19 pages PMID: 22110473; doi: 10.1155/2011/596060
  7. Maymone AC, Baillargeon JP, Ménard J, Ardilouze JL. Oral hypoglycemic agents for gestational diabetes mellitus? Expert Opinion On Drug Safety 2011; 10(2):227-38.
  8. Mahdavian M, Hivert MF, Baillargeon JP, Menard J, Ouellet A, Ardilouze JL. Gestational diabetes mellitus: simplifying the international association of diabetes and pregnancy diagnostic algorithm using fasting plasma glucose: comment on agarwal, dhatt, and shah. Diabetes Care 2010; 33(11): e145.
  9. Ardilouze JL, Mahdavian M, Baillargeon JP*. Brick by brick: Metformin for gestational diabetes mellitus? Expert Rev Endocrinol Metab 2010; 5
  10. Baptiste CG, Battista MC, Trottier A, Baillargeon JP*. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem MolBiol 2010; 122(1-3): 42-52.Grant: CIHR IGO94420
  11. Massicotte MH, Langlois F, Baillargeon JP*. Current procedures for managing polycystic ovary syndrome. Expert Rev of Obstet Gynecol 2010; 5(1): 77-91.
  12. Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol 2009; 147(2):120-123.
  13. Brassard M, AinMelk Y, Baillargeon JP*. Basic infertility including polycystic ovary syndrome. Med Clin North Am 2008; 92(5): 1163-1192.
  14. Baillargeon JP*, Carpentier AC. Correlates between hyperinsulinism and hyperandrogenemia? Fertil Steril 2008; 89(4): 1034. Grants: CIHR MOP62946, FRSQ #2834
  15. Roberge C, Carpentier AC, Langlois MF, Baillargeon JP, Ardilouze JL, Maheux P, Gallo-Payet N. Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity. Am J Physiol Endocrinol Metab. 2007; 293(6): E1465-1478.
  16. Pesant MH, Baillargeon JP*. Ovulation induction in polycystic ovary syndrome—how do metformin and clomiphene citrate compare? Nat Clin Pract Endocrinol Metab 2007; 3(7): 512-513.
  17. Baillargeon JP*, Legro RS. Should metformin be used as first line therapy for fertility in patients with PCOS? Sexuality, Reproduction & Menopause 2007; 5(2): 17-19.
  18. Pesant MH, Baillargeon JP*. Comparing rosiglitazone with ethinylestradiol/cyproterone acetate in the treatment of polycystic ovary syndrome. Expert Rev of Obstet Gynecol 2006; 1(1): 81-92.
  19. Baillargeon JP*, Nestler JE. Polycystic ovary syndrome: a syndrome of androgenic hypersensitivity to insulin? J Clin Endocrinol Metab 2006; 91(1): 22-24. Grants: CIHR MOP62946, FRSQ #2834
  20. Baillargeon JP*. Use of insulin sensitizers in polycystic ovarian syndrome. Curr Opin Investig Drugs 2005; 6(10): 1012-1022.
  21. Baillargeon JP*. L'INSULINE : Son action dans le syndrome des ovaires polykystiques. Nutritions & facteurs de risque 2005; 3(19): 276-280. Grants: CIHR MOP62946, FRSQ #2834
  22. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Nestler JE. A Modern Medical Quandary: Polycystic Ovary Syndrome, Insulin Resistance, and Oral Contraceptive Pills. J Clin Endocrinol Metab 2003; 88(5): 1927-1932.
  23. Baillargeon JP, Iuorno MJ, Nestler JE. Insulin Sensitizers for polycystic ovary syndrome. Clinical Obstetrics and Gynecology 2003; 46(2): 325-340.
  24. Baillargeon JP, Iuorno MJ, Nestler JE. Comparison of metformin and thiazolidinediones in the management of polycystic ovary syndrome. Curr Opin Endocrinol Diabetes 2002; 9(4): 303-311.
  25. Baillargeon JP, Lepage S, Larrivée L, Roy MA, Maheux P. Intensive surveillance and treatment of dyslipidemia in the postinfarct patient: evaluation of a nurse-oriented management approach (comment). Can J Cardiology 2001; 17(7): 767-768.

Awards:

  1. Prix Jean-de-Margerie.Award of the Faculté de médecine et des sciences de la santé de l’Université de Sherbrooke. This award recognizes the excellence of a publication in the field of clinical or basic science, 2016.
  2. Université de Sherbrooke – Faculté de médecine et des sciences de la santé. Dean's roll of honour attributed to the 10% superior faculty members who distinguished themselves by their outstanding performance and commitment to the Faculty. May 28th 2015 & May 10th 2016.
  3. Canadian Association for Medical Education (CAME) Certificate of merit award. Canadian Conference on Medical Education, April 27, 2014.
  4. 2011 CSEM Young Investigator Award. Canadian Society of Endocrinology and Metabolism
  5. Fonds de Recherche en Santé du Québec, Réduire l'impact de l'obésité sur la santé métabolique et endocrinienne, particulièrement chez la femme : rôle de l'obésité dans le développement du syndrome des ovaires polykystiques (via les acides gras), et sa prise en charge en première ligne, Senior Clinical Investigator Salary Support, (1st rank in the committee Clinic and Epidemilogy)
  6. Fonds de Recherche en Santé du Québec, Rôle de l’action de l’insuline dans l’hyperandrogénémie des femmes avec un syndrome des ovaires polykystiques, Junior 2 Clinical Investigator Salary Support
  7. Fonds de Recherche en Santé du Québec, Rôle respectif de l'insuline et de la LH dans l'hyper-réponse stéroïdienne ovarienne chez les femmes non obèses avec syndrome des ovaires polykystiques et niveaux normaux d'insuline, Junior 1 Clinical Investigator Salary Support